Adaptimmune    Print Page  |  Close Window

2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
04/18/19Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
- Presentation to include overview of substantial progress of Adaptimmune’s off-the-shelf SPEAR T-cell platform - - Data will show that hiPSC-derived allogeneic SPEAR T-cells have a T-cell phenotype and demonstrate tumor antigen-specific activation in vitro - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 18, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces an oral presentation by Dr. Jo Brewer, VP of Platform S... 
Printer Friendly Version
04/02/19Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
PHILADELPHIA and OXFORD, United Kingdom, April 02, 2019 (GLOBE NEWSWIRE) --  Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from the first dose cohort of the ADP-A2AFP study at the annual AACR meeting. “We did not observe clinically significant liver toxicity in the two patients treated at a dose of 100 million transduced cells, and these data ... 
Printer Friendly Version
04/01/19Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
- Preclinical data show that next generation SPEAR T-cells may improve long term T-cell functions as well as antitumor activity - PHILADELPHIA and OXFORD, United Kingdom, April 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented promising preclinical data at the annual AACR meeting from its next generation SPEAR T-cell targeting MAGE-A4. This next generation SPEAR T-cell, known as ADP-A2M4CD8, expresses the CD8α co-rec... 
Printer Friendly Version
02/27/19CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
PHILADELPHIA and OXFORD, United Kingdom, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Adaptimmune Therapeutics plc (Nasdaq:ADAP), please note that the third subheadline should read, "Treating patients in expansion phases of all ADP-A2M10 and ADP-A2M4 studies at target doses of 5 billion cells (with doses up to 10 billion cells)," specifically "5 billion cells" rather than "1 billion cells" as previously stated. Additionally, under the "Building... 
Printer Friendly Version
02/27/19Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
- On track for clinical data update from trials in multiple solid tumors at the Q1 2019 earnings update call in May - - Completed initial safety cohorts for ADP-A2M10 (MAGE-A10) in lung and triple tumor studies as well as ADP-A2M4 (MAGE-A4) basket study - - Treating patients in expansion phases of all ADP-A2M10 and ADP-A2M4 studies at target doses of 1 billion cells (with doses up to 10 billion cells) - - Completed Cohort 1 for safety in ADP-A2AFP (AFP) study and treating patients in safety C... 
Printer Friendly Version
02/07/19Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
PHILADELPHIA and OXFORD, United Kingdom, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2018 and provide a general business update before the U.S. markets open on Wednesday, February 27, 2019. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) on the same day. The press release and the ... 
Printer Friendly Version
01/07/19Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in patients with hepatocellular carcinoma (liver cancer) to the second dose cohort. The SRC has also endorsed moving to the expansion phase of the ADP-A2M10 (MAGE-A10) lung cancer study. Across both studies, mos... 
Printer Friendly Version